Adnexus Therapeutics

Compound Therapeutics, Inc. Raises $15.5 Million to Advance Product Pipeline Into Clinic

Compound Therapeutics, Inc. Raises $15.5 Million to Advance Product Pipeline Into Clinic

January 18, 2005

WALTHAM, Mass., Jan. 18 /PRNewswire/ -- Compound Therapeutics, Inc., a privately held biotechnology company, today announced that it has raised an additional $15.5 million in an expansion of its Series A financing. These funds will be used to advance Compound's lead oncology product candidate into the clinic and to build the company's pipeline by moving additional programs into preclinical development. Compound is developing the next generation of biotherapeutics with its AdNectin and AdZyme technologies.

Flagship Ventures Has Moved Effective January 31, 2005

Flagship Ventures Has Moved Effective January 31, 2005

January 31, 2005


is pleased to announce

our new address effective January 31, 2005:

e-Dialog, Inc.

e-Dialog Posts 49 Percent Revenue Growth in 2004

e-Dialog Posts 49 Percent Revenue Growth in 2004

February 1, 2005

Emphasis on Strategy and Flexible Service Offerings Fuels Momentum in the Marketplace

BG Medicine, Inc.

Beyond Genomics Becomes BG Medicine, Appoints Pieter Muntendam, MD President; Moves Underscore Sharpened Focus On Drug Development Applications

Beyond Genomics Becomes BG Medicine, Appoints Pieter Muntendam, MD President; Moves Underscore Sharpened Focus On Drug Development Applications

February 3, 2005

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 3, 2005--Beyond Genomics, Inc. today announced its name change to BG Medicine Inc. The company also announced the appointment of Pieter Muntendam, MD as its new President to lead the company's business operations and strategy. BG Medicine's new name and new leadership reflect the decision to focus on high-value drug development applications of its proprietary Systems Pharmacology platform that is based on the scientific advances in the nascent Systems Biology field.

Affinnova, Inc.

Forbes Cover Article Features Flagship Portfolio Company Affinnova

Forbes Cover Article Features Flagship Portfolio Company Affinnova

February 6, 2005

Flagship founded Affinnova in 2000 to bring the concepts and techniques of Darwinian Evolution to product design. The company's patent-pending technology, IDEA(TM), leverages the Internet as a medium to combine the real-time input of thousands of consumers to select iteratively from among thousands or millions of possible designs. The designs in turn are generated by proprietary software based on genetic algorithms. In its February issue cover story titled "Have It Your Way", Forbes Magazine features Affinnova as a leading example of consumer-centric innovation.

Selventa

Genstruct Appoints Dr. Michael Pavia to Its Board of Directors

Genstruct Appoints Dr. Michael Pavia to Its Board of Directors

February 14, 2005

CAMBRIDGE, Mass., Feb. 14 /PRNewswire/ -- Genstruct, Inc., a knowledge-driven discovery company using systems biology to discover biomarkers to increase the effectiveness of drug discovery and development, today announced the appointment of Michael R. Pavia, Ph.D., former chief technology officer (CTO) of Millennium Pharmaceuticals, to its Board of Directors.

BG Medicine, Inc.
Selventa

Cover Article in Chemical & Engineering News Features Flagship Portfolio Companies BG Medicine and Genstruct

Cover Article in Chemical & Engineering News Features Flagship Portfolio Companies BG Medicine and Genstruct

February 16, 2005

Two of Flagship's portfolio companies, BG Medicine and Genstruct, are featured in the cover article of this month's Chemical & Engineering News. Both are the result of Flagship's venture creation efforts over the past several years, and are recognized as leaders in the emerging field of Systems Biology. Both companies have also had significant, sustained involvement by Flagship as they have evolved and matured.

AVEO Pharmaceuticals, Inc.

GENPATH PHARMACEUTICALS BECOMES AVEO PHARMACEUTICALS

GENPATH PHARMACEUTICALS BECOMES AVEO PHARMACEUTICALS

March 1, 2005

Cambridge, MA, March 1, 2005 – GenPath Pharmaceuticals, Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has changed its corporate name to AVEO Pharmaceuticals, Inc.

Morphotek, Inc.

Morphotek Announces Acceptance of Investigational New Drug Application for MORAb-003, a humanized monoclonal antibody for the treatment of advanced ovarian cancer

Morphotek Announces Acceptance of Investigational New Drug Application for MORAb-003, a humanized monoclonal antibody for the treatment of advanced ovarian cancer

March 28, 2005

Exton, PA, March 28, 2005– Morphotek, Inc. today announced that the United States Food and Drug Administration has accepted its Investigational New Drug (IND) Application for treatment of advanced ovarian cancer with MORAb-003, a humanized monoclonal antibody. The Phase I clinical study is designed as an open label single dose escalation safety study in patients with chemo-refractive ovarian cancer.

Black Duck Software, Inc.

Black Duck Launches protexIP/OnDemand Hosted Service To Analyze Software for Open Source License Compliance

Black Duck Launches protexIP/OnDemand Hosted Service To Analyze Software for Open Source License Compliance

March 28, 2005

Lets Software Developers, Outsourcers, and Due Diligence Teams Meet Compliance Deadlines with Easy-to-Use, Automated Service